Intramyocardial and intracoronary autologous bone marrow-derived mesenchymal stromal cell treatment in chronic severe dilated cardiomyopathy

Cytotherapy

Volumn 13, Issue 7, 2011, Pages 814-821

  Chin, Sze Piaw ^a   Poey, Alfred C ^b   Wong, Chee Yin ^c   Chang, Sau Kong ^b   Tan, Chiang Soo ^b   Ng, Mei Theng ^c   Chew, Kee Hock ^b   Lam, Kai Huat ^d   Cheong, Soon Keng ^e  

^a Mawar Hospital   (Malaysia)

^b Penang Adventist Hospital   (Malaysia)

^c Cytopeutics   (Malaysia)

^d Assunta Hospital   (Malaysia)

^e UNIVERSITI TUNKU ABDUL RAHMAN   (Malaysia)

Author keywords

Dilated cardiomyopathy; Intracoronary injection; Intramyocardial injection; Mesenchymal stromal cell

Indexed keywords

ADULT; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CHRONIC DISEASE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; DISEASE SEVERITY; ENDOTHELIUM CELL; EXTRACORPOREAL CIRCULATION; FEASIBILITY STUDY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; SAFETY; SCAR; SYMPTOM; TREATMENT OUTCOME;

EID: 84860390525     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.574118     Document Type: Article

References (28)

1. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-40.
2. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347: 1397-402.
3. Mann DL, Bristow MR. Mechanisms and models in heart failure: The biomechanical model and beyond. Circulation. 2005;111:2837-49.
4. Bax JJ, Visser FC, Poldermans D, Elhendy A, Cornel JH, Boersma E, et al. Relationship between preoperative viability and postoperative improvement in LVEF and heart failure symptoms. J Nucl Med. 2001;42:79-86.
5. Lipiecki J, Durel N, Ponsonnaille J. Which patients with ischemic heart disease could benefi t from cell replacement therapy? Eur Heart J. 2006;8(Suppl H):H3-7.
6. Boyle AJ, Schulman SP, Hare JM, Oettgen P. Stem cell therapy for cardiac repair: Ready for the next step. Circulation. 2006;114:339-52.
7. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, et al. Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. Arch Intern Med. 2007;167:989-97.
8. Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, Bartunek J, et al. A collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol. 2007;50:1761-7.
9. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, et al. Autologous bone marrow-derived stemcell transfer in patients with ST-segment elevation myocardial infarction: Double-blind, randomised controlled trial. Lancet. 2006;367:113-21.
10. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, et al. Intracoronary bone marrow cell transfer after myocardial infarction: Eighteen months'follow-up data from the randomized, controlled BOOST (BOnemarrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation.2006;113:1287- 94.
11. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004;94:92-5.
12. Katritsis DG, Sotiropoulou PA, Karvouni E, Karabinos I, Korovesis S, Perez SA, et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv. 2005;65:321-9.
13. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002; 105:93-8.
14. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noel D. Immunosuppression by mesenchymal stem cells: Mechanisms and clinical applications. Stem Cell Res Ther. 2010;1:2 doi:10.1186/scrt2.
15. Guarita-Souza CL, de Carvalho KAT, Francisco JC, Simeoni R, Faria-Neto JR, Cellular transplantation for the treatment of non-ischaemic dilated cardiomyopathies. Eur Heart J Suppl. 2008;10:K7-10.
16. Chin SP, Poey AC, Wong CY, Chang SK, Teh W, Mohr TJ, et al. Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy. Cytotherapy. 2010;12:31-7.
17. Wong CY, Cheong SK, Mok PL, Leong CF. Differentiation of human mesenchymal stem cells into mesangial cells in post-glomerular injury murine model. Pathology. 2008;40: 52-7.
18. Law PK, Chin SP, Hung HD, Nguyen TN, Feng QZ. Delivery of biologics for angiogenesis and myogenesis. In: Nguyen TN, Colombo A, Hu D, Grines CL, Saito S. Practical Handbook of Advanced Interventional Cardiology. 3rd ed. New York: Blackwell; 2008. p. 583-95.
19. Sherman W, Martens TP, Viles-Gonzalez JF, Siminiak T. Catheter-based delivery of cells to the heart. Nat Clin Pract Cardiovasc Med. 2006;3(Suppl 1):S57-64.
20. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood.2006;108:2114-20.
21. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, et al. Transendocardial autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107:2294-302
22. Assmus B, Honold J, Schä c hinger V, Britten MB, Fischer- Rasokat U, Lehmann R, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006;355:1222-32.
23. Bax JJ, Poldermans D, Elhendy A, Cornel JH, Boersma E, Rambaldi R, et al. Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. J Am Coll Cardiol. 1999;34:163-9.
24. Schinkel AF, Poldermans D, Rizzello V, Vanoverschelde JL, Elhendy A, Boersma E, et al. Why do patients with ischaemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization? J Thorac Cardiovasc Surg. 2004;127:385-90.
25. Bax JJ, Schinkel AF, Boersma E, Elhendy A, Rizzello V, Maat A, et al. Extensive left ventricular remodeling does not allow viable myocardium to improve in left ventricular ejection fraction after revascularization and is associated with worse long-term prognosis. Circulation. 2004;110:II18-22.
26. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: The scientifi c foundations of cardiac repair. J Clin Invest. 2005;115:572-83.
27. Chen S, Liu Z, Tian N, Zhang J, Yei F, Duan B, et al. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol. 2006;18:552-6.
28. Gao LR, Wang ZG, Zhu ZM, Fei YX, He S, Tian HT, et al. Effect of intracoronary transplantation of autologous bone marrow-derived mononuclear cells on outcomes of patients with refractory chronic heart failure secondary to ischemic cardiomyopathy. Am J Cardiol. 2006;98:597-602.